Cingulate Therapeutics — Form D
Cingulate Therapeutics of Kansas City, KS, a company, filed a Form D exempt-offering notice with the SEC on 2018-07-11. $15.6M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2018-07-11
- Form: D
- Accession: 0001593151-18-000005
- Industry: Pharmaceuticals
- Exemptions: 06b, 4a5
- Amount sold: $15.6M
- Minimum investment: $100K
- Investors: 133
- Date of first sale: 2013-11-14
- Security types: equity, debt
- Revenue range: No Revenues
- SEC file number: 021-316588
Issuer
- Name: Cingulate Therapeutics
- CIK: 0001593151
- Entity type: Limited Liability Company
- Jurisdiction: DELAWARE
- Incorporated: 2012
- Address: 1901 W. 47th Place, Kansas City, KS, 66205
- Phone: 9139422300
Officers, directors & promoters (15)
| Name | Role | Location |
|---|
| Jeff J Hargroves | Director | Kansas City, KS |
| Shane J Schaffer | Director | Kansas City, KS |
| Shane J Schaffer | Executive Officer | Kansas City, KS |
| Jeff J Conroy | Director | Kansas City, KS |
| Peter J Werth | Director | Kansas City, KS |
| Patrick J Gallagher | Director | Kansas City, KS |
| Matthew N Brams | Director | Houston, TX |
| Matthew N Brams | Executive Officer | Houston, TX |
| Louis George Van Horn | Executive Officer | Village of Loch Lloyd, MO |
| Craig Steven Gilgallon | Executive Officer | Morristown, NJ |
| Laurie A Myers | Director | Kansas City, MO |
| Laurie A Myers | Executive Officer | Kansas City, MO |
| Raul R Silva | Executive Officer | Upper Grandview, NY |
| Arthur B Straughn | Director | Cordova, TN |
| Craig Stephen Tashjy | Executive Officer | Morristown, NJ |
Other filings by this issuer (6)
More